Market Overview:
The global ketorolac tromethamine market is expected to register a CAGR of 5.5% during the forecast period, 2018-2030. The market growth can be attributed to the increasing prevalence of pain and ophthalmic surgeries across the globe. In addition, growing awareness about the benefits of ketorolac tromethamine is also propelling the growth of this market. Based on type, the global ketorolac tromethamine market has been segmented into injection, ophthalmic, nasal and oral tablet. The injection segment is estimated to account for a major share in terms of revenue in 2018 and is projected to maintain its dominance throughout 2030. This can be attributed to its high usage rates for short-term treatment of pain across various applications such as hospitals & clinics, ambulatory surgical centers (ASCs) and home healthcare settings. Based on application, short-term treatment of pain accounted for a majority share in 2017 and is anticipated to maintain its dominance throughout 2030 owing to rising incidence rates of various types of pain including postoperative pain, cancerpainand dentalpainamong others . However ,the ophthalmic surgery segmentis projectedto witness highest CAGR overthe forecast period owingto increasing demand for minimally invasive surgeries coupled with rising prevalenceof eye diseases& disorders worldwide .
Product Definition:
Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve pain and inflammation. It is used to treat moderate to severe pain, including pain after surgery.
Injection:
Injection is a medical procedure used to treat pain in people who are suffering from osteoarthritis, ankylosing spondylitis or back pain. The drug works by reducing the cartilage that covers the joints and allows the free flow of synovial fluid. It reduces inflammation and enhances blood flow to reduce joint pain.
Injection is available as a sterile solution for oral use in both solid (powdered).
Ophthalmic:
Ophthalmic is the branch of medical science that deals with eyes and vision. Vision correction, treatment of eye diseases, and prevention from visual impairment are some of the functions performed by ophthalmic medicines. The ketorolac tromethamine used for eye inflammation is known as Ophthalmic drug or simply “ocular”.
Application Insights:
The short-term treatment of pain segment held the largest share of over 70.0% in 2017. Ketorolac tromethamine is used for acute pain due to sprains, strains and arthritis. It is also used for chronic non-cancerous pain in postoperative patients as well as during labor and delivery pains. The drug has a high safety profile with no known side effects other than mild stomach upset if ketorolac tromethamine injection is given intravenously (i.v.). However, this effect can be minimized by giving the drug i/v at a slow rate and gradually increasing the dose over 1 to 2 days until an optimal response is obtained from patient¢â‚¬â„¢s body without any adverse effects on its own accord.
Regional Analysis:
North America dominated the global market in 2017 owing to the presence of a large number of pharmaceutical companies, which are engaged in ketorolac tromethamine production. The region is expected to maintain its dominance over the forecast period as well. This can be attributed to increasing R&D activities and rising healthcare expenditure by government and private sectors across countries such as U.S., Canada, and Mexico.
Asia Pacific is anticipated to witness lucrative growth during the forecast period due to factors such as growing medical tourism industry, improving healthcare infrastructure & facilities along with rising disposable income among middle-class population groups especially in China & India. These aforementioned factors are also contributing towards increased demand for various pain management therapies including ketorolac tromethamine injection over other alternatives available in Asia Pacific region at present time (2017).
Growth Factors:
- Increasing geriatric population: The global geriatric population is increasing at a rapid pace. This will lead to an increase in the demand for ketorolac tromethamine, as it is one of the most commonly prescribed drugs for pain relief in this population.
- Rising incidence of chronic pain: The incidence of chronic pain is on the rise due to factors such as increased life expectancy, obesity, and physical inactivity. This will lead to an increase in the demand for ketorolac tromethamine as a treatment option for chronic pain relief.
- Growing awareness about analgesics: There is growing awareness among people about the benefits of analgesics such as ketorolac tromethamine for relieving various types of pain. This will lead to an increase in its use worldwide.
Scope Of The Report
Report Attributes
Report Details
Report Title
Ketorolac Tromethamine Market Research Report
By Type
Injection, Ophthalmic, Nasal, Oral tablet
By Application
Short-term treatment of pain, Ophthalmic Surgery
By Companies
Pfizer, Omeros Corporation, Egalet US Inc., Allergan, Dr. Reddy’s Laboratories, Teva, Mylan, West Ward Pharmaceuticals, Fresenius Kabi, Apotex, Sandoz, Amphastar Pharmaceuticals, Gland Pharma Limited, Akorn, Sun Pharmaceutical, Sagent Pharmaceuticals, Aurobindo Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
222
Number of Tables & Figures
156
Customization Available
Yes, the report can be customized as per your need.
Global Ketorolac Tromethamine Market Report Segments:
The global Ketorolac Tromethamine market is segmented on the basis of:
Types
Injection, Ophthalmic, Nasal, Oral tablet
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Short-term treatment of pain, Ophthalmic Surgery
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Omeros Corporation
- Egalet US Inc.
- Allergan
- Dr. Reddy’s Laboratories
- Teva
- Mylan
- West Ward Pharmaceuticals
- Fresenius Kabi
- Apotex
- Sandoz
- Amphastar Pharmaceuticals
- Gland Pharma Limited
- Akorn
- Sun Pharmaceutical
- Sagent Pharmaceuticals
- Aurobindo Pharma
Highlights of The Ketorolac Tromethamine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Injection
- Ophthalmic
- Nasal
- Oral tablet
- By Application:
- Short-term treatment of pain
- Ophthalmic Surgery
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Ketorolac Tromethamine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Ketorolac tromethamine is a medication used to relieve pain and inflammation. It is also used to reduce fever. Ketorolac tromethamine belongs to the class of medications called nonsteroidal anti-inflammatory drugs (NSAIDs).
Some of the key players operating in the ketorolac tromethamine market are Pfizer, Omeros Corporation, Egalet US Inc., Allergan, Dr. Reddy’s Laboratories, Teva, Mylan, West Ward Pharmaceuticals, Fresenius Kabi, Apotex, Sandoz, Amphastar Pharmaceuticals, Gland Pharma Limited, Akorn, Sun Pharmaceutical, Sagent Pharmaceuticals, Aurobindo Pharma.
The ketorolac tromethamine market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Ketorolac Tromethamine Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Ketorolac Tromethamine Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Ketorolac Tromethamine Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Ketorolac Tromethamine Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Ketorolac Tromethamine Market Size & Forecast, 2020-2028
4.5.1 Ketorolac Tromethamine Market Size and Y-o-Y Growth
4.5.2 Ketorolac Tromethamine Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Injection
5.2.2 Ophthalmic
5.2.3 Nasal
5.2.4 Oral tablet
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Short-term treatment of pain
6.2.2 Ophthalmic Surgery
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Ketorolac Tromethamine Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Ketorolac Tromethamine Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Injection
9.6.2 Ophthalmic
9.6.3 Nasal
9.6.4 Oral tablet
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Short-term treatment of pain
9.10.2 Ophthalmic Surgery
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Injection
10.6.2 Ophthalmic
10.6.3 Nasal
10.6.4 Oral tablet
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Short-term treatment of pain
10.10.2 Ophthalmic Surgery
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Injection
11.6.2 Ophthalmic
11.6.3 Nasal
11.6.4 Oral tablet
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Short-term treatment of pain
11.10.2 Ophthalmic Surgery
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Injection
12.6.2 Ophthalmic
12.6.3 Nasal
12.6.4 Oral tablet
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Short-term treatment of pain
12.10.2 Ophthalmic Surgery
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Injection
13.6.2 Ophthalmic
13.6.3 Nasal
13.6.4 Oral tablet
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Short-term treatment of pain
13.10.2 Ophthalmic Surgery
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Ketorolac Tromethamine Market: Competitive Dashboard
14.2 Global Ketorolac Tromethamine Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Omeros Corporation
14.3.3 Egalet US Inc.
14.3.4 Allergan
14.3.5 Dr. Reddy’s Laboratories
14.3.6 Teva
14.3.7 Mylan
14.3.8 West Ward Pharmaceuticals
14.3.9 Fresenius Kabi
14.3.10 Apotex
14.3.11 Sandoz
14.3.12 Amphastar Pharmaceuticals
14.3.13 Gland Pharma Limited
14.3.14 Akorn
14.3.15 Sun Pharmaceutical
14.3.16 Sagent Pharmaceuticals
14.3.17 Aurobindo Pharma
